Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.90 +1.6%	$1.76	$1.21 ▼ $3.81	$46.92M	0.68	266,476 shs	82,732 shs
ANVS Annovis Bio	$2.10 -3.4%	$2.16	$1.11 ▼ $17.88	$42.28M	1.62	754,054 shs	440,443 shs
RNXT RenovoRx	$1.28 -5.2%	$1.21	$0.75 ▼ $1.69	$49.37M	1.32	98,216 shs	243,724 shs
UBX UNITY Biotechnology	$0.77 -1.7%	$0.84	$0.66 ▼ $3.10	$13.51M	1.05	165,355 shs	54,338 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	+0.53%	-7.32%	+5.56%	-0.52%	+18.75%
ANVS Annovis Bio	-3.19%	-19.75%	-13.39%	+27.42%	-63.42%
RNXT RenovoRx	-5.19%	-7.25%	-1.16%	+28.00%	+13.27%
UBX UNITY Biotechnology	-1.73%	-4.17%	+13.27%	-32.33%	-44.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	0.5567 of 5 stars	1.0	0.0	0.0	1.1	2.5	1.3
ANVS Annovis Bio	2.1295 of 5 stars	3.5	1.0	0.0	2.6	1.7	0.6
RNXT RenovoRx	2.9814 of 5 stars	3.5	5.0	0.0	2.7	1.7	0.0
UBX UNITY Biotechnology	3.8185 of 5 stars	3.3	2.0	4.7	2.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	2.00	Hold	$1.67	-12.28% Downside
ANVS Annovis Bio	3.00	Buy	$30.25	1,343.23% Upside
RNXT RenovoRx	3.00	Buy	$7.25	466.41% Upside
UBX UNITY Biotechnology	2.50	Moderate Buy	$3.75	386.13% Upside

Current Analyst Ratings Breakdown

Latest UBX, AADI, RNXT, and ANVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
6/5/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $11.50
5/27/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$4.00 ➝ $2.00
5/19/2025	RNXT RenovoRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/16/2025	UBX UNITY Biotechnology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$6.00 ➝ $1.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
4/28/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
4/23/2025	UBX UNITY Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/23/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/4/2025	RNXT RenovoRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.87	N/A	N/A	$4.29 per share	0.44
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
RNXT RenovoRx	$40K	1,170.24	N/A	N/A	$0.19 per share	6.74
UBX UNITY Biotechnology	$240K	55.32	N/A	N/A	$0.39 per share	1.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	8/5/2025 (Estimated)
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
RNXT RenovoRx	-$8.81M	-$0.40	N/A	N/A	N/A	N/A	-119.58%	-88.01%	8/12/2025 (Estimated)
UBX UNITY Biotechnology	-$25.99M	-$1.62	N/A	N/A	N/A	N/A	-246.82%	-58.81%	7/22/2025 (Estimated)

Latest UBX, AADI, RNXT, and ANVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.08	$0.23 million	$0.20 million
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A
4/22/2025	Q1 2025	UBX UNITY Biotechnology	-$0.43	-$0.43	N/A	-$0.43	N/A	N/A
3/31/2025	Q4 2024	RNXT RenovoRx	-$0.12	-$0.13	-$0.01	-$0.12	$0.17 million	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A
UBX UNITY Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
ANVS Annovis Bio	N/A	10.68	10.68
RNXT RenovoRx	N/A	9.07	9.07
UBX UNITY Biotechnology	N/A	1.95	1.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
ANVS Annovis Bio	15.83%
RNXT RenovoRx	3.10%
UBX UNITY Biotechnology	29.49%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
ANVS Annovis Bio	20.80%
RNXT RenovoRx	9.13%
UBX UNITY Biotechnology	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
RNXT RenovoRx	6	36.57 million	33.23 million	Not Optionable
UBX UNITY Biotechnology	60	17.21 million	16.21 million	Optionable

UBX, AADI, RNXT, and ANVS Headlines

Recent News About These Companies

Unity Biotechnology Inc News (UBX) - Investing.com

June 26 at 1:10 PM | investing.com

UBX Unity Biotechnology, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)

May 28, 2025 | msn.com

Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities

May 18, 2025 | theglobeandmail.com

Bay Area biotech company Unity lays off every single worker, including CEO

May 6, 2025 | msn.com

Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce

May 5, 2025 | msn.com

South San Francisco biotech company lays off entire workforce, including CEO

May 5, 2025 | msn.com

Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles

May 5, 2025 | fiercebiotech.comF

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

May 1, 2025 | globenewswire.com

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325

April 25, 2025 | ophthalmologytimes.comO

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

April 22, 2025 | globenewswire.com

Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology price target lowered to $4 from $6 at Chardan

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology announces results from ASPIRE Phase 2b study in DME

March 25, 2025 | markets.businessinsider.com

Unity reports topline outcomes from trial of diabetic macular oedema therapy

March 25, 2025 | msn.com

UNITY Biotechnology tanks on mixed results for eye disease drug

March 25, 2025 | thepharmaletter.comT

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

March 25, 2025 | zacks.com

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

March 24, 2025 | finance.yahoo.com

Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema

March 24, 2025 | ophthalmologytimes.comO

UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial

March 24, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UBX, AADI, RNXT, and ANVS Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.90 +0.03 (+1.60%)

As of 06/26/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Annovis Bio NYSE:ANVS

$2.10 -0.07 (-3.41%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$2.13 +0.03 (+1.62%)

As of 06/27/2025 07:15 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

RenovoRx NASDAQ:RNXT

$1.28 -0.07 (-5.19%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.35 +0.07 (+5.39%)

As of 06/27/2025 07:56 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

UNITY Biotechnology NASDAQ:UBX

$0.77 -0.01 (-1.73%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.79 +0.01 (+1.89%)

As of 06/27/2025 07:25 PM Eastern

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time